Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00228462 |
This study is being carried out to see if quetiapine (Seroquel) is effective in preventing patients from a schizophrenic relapse when studied for a long time (1 year) and if so, how it compares with non-active treatment.
Condition | Intervention | Phase |
---|---|---|
Schizophrenia |
Drug: Seroquel (quetiapine) |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | A 1-Year, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Phase 3 Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Sustained-Release Quetiapine Fumarate (SEROQUEL) or Placebo (Abbreviated) |
Enrollment: | 197 |
Study Start Date: | March 2005 |
Study Completion Date: | April 2006 |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Bulgaria | |
Investigative Site | |
Sofia, Bulgaria | |
Investigative Site | |
Radnevo, Bulgaria | |
Investigative Site | |
Burgas, Bulgaria | |
Poland | |
Investigative Site | |
Bydgoszcz, Poland | |
Investigative Site | |
Tuszyn, Poland |
Study Director: | AstraZeneca Seroquel Medical Science Director, MD | AstraZeneca |
Study ID Numbers: | D1444C00004 |
Study First Received: | September 27, 2005 |
Last Updated: | December 14, 2007 |
ClinicalTrials.gov Identifier: | NCT00228462 History of Changes |
Health Authority: | European Union: European Medicines Agency; United States: Food and Drug Administration |
Schizophrenia |
Schizophrenia Quetiapine Tranquilizing Agents Mental Disorders Psychotropic Drugs |
Central Nervous System Depressants Psychotic Disorders Antipsychotic Agents Schizophrenia and Disorders with Psychotic Features |
Schizophrenia Quetiapine Tranquilizing Agents Mental Disorders Therapeutic Uses Physiological Effects of Drugs |
Psychotropic Drugs Central Nervous System Depressants Antipsychotic Agents Central Nervous System Agents Pharmacologic Actions Schizophrenia and Disorders with Psychotic Features |